Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3

BACKGROUND: The most frequently reported treatment‐related adverse event in clinical trials with the cyclin‐dependent kinase 4/6 (CDK4/6) inhibitor palbociclib is neutropenia. Allelic variants in ABCB1 and ERCC1 might be associated with early occurrence (i.e., end of week 2 treatment) of grade 3/4 n...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiroji, Umeyama, Yoshiko, Liu, Yuan, Zhang, Zhe, Schnell, Patrick, Mori, Yuko, Fletcher, Olivia, Marshall, Jean‐Claude, Johnson, Jillian G., Wood, Linda S., Toi, Masakazu, Finn, Richard S., Turner, Nicholas C., Bartlett, Cynthia Huang, Cristofanilli, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265363/
https://www.ncbi.nlm.nih.gov/pubmed/33955129
http://dx.doi.org/10.1002/onco.13811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265363/
https://www.ncbi.nlm.nih.gov/pubmed/33955129
http://dx.doi.org/10.1002/onco.13811

Ejemplares similares